Saturday 17 October 2026
Export CORT’s income statement to Excel — free account
Corcept Therapeutics Incorporated
CORT Healthcare Biotechnology
Corcept Therapeutics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $761.4 million, up 12.8% from fiscal 2024. In the quarter to June 2026, revenue grew 31.7%, EPS grew 21.2% and free cash flow fell 29.9%, each against the same quarter a year earlier. Revenue growth for ten consecutive years; insiders bought in the last twelve months.
110.16
3.21
−2.83%
Follow CORT
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
37.02 | 37.33 | 23.46 | 21.23 | 22.76 | 28.43 | 14.58 | 20.55 | 16.05 | 105.44 |
Piotroski F-Score |
4 | 6 | 6 | 8 | 7 | 6 | 6 | 6 | 6 | 8 |
Altman Z-Score |
14.11 | 22.11 | 20.51 | 18.86 | 31.75 | 39.90 | 22.52 | 27.82 | 42.41 | 13.37 |
P/S ratio |
4.75 | 7.71 | 5.19 | 5.36 | 6.26 | 8.53 | 4.51 | 6.13 | 12.94 | 10.01 |
P/FCF ratio |
25.49 | 26.52 | 19.78 | 17.96 | 13.68 | 20.03 | 10.25 | 13.36 | 34.03 | 44.72 |
Altman Z″-Score (non-manufacturers) |
8.97 | 10.22 | 11.64 | 14.21 | 15.09 | 18.28 | 15.38 | 13.02 | 8.35 | (9.04) |
Beneish M-Score |
(2.76) | (2.26) | (2.14) | (2.83) | (2.69) | (2.65) | (2.76) | (3.23) | 4.42 | (2.48) |
P/Operating CF |
94.01 | 86.61 | 452.52 | 64.51 | 46.33 | 86.09 | 28.56 | 71.61 | 82.76 | 178.11 |
P/B ratio |
5.58 | 7.65 | 4.94 | 4.29 | 6.09 | 5.77 | 3.73 | 5.59 | 10.78 | 19.67 |
Price to Tangible BV |
5.58 | 7.65 | 4.94 | 4.29 | 6.09 | 5.77 | 3.73 | 5.59 | 10.78 | 19.67 |
EV/Sales |
4.28 | 7.16 | 4.45 | 4.31 | 5.68 | 7.32 | 3.65 | 5.37 | 12.47 | 9.60 |
EV/EBITDA |
78.33 | 37.96 | 21.33 | 14.75 | 15.61 | 19.85 | 9.84 | 15.32 | 37.46 | 75.89 |
EV/Operating CF |
22.94 | 24.38 | 16.93 | 14.40 | 12.37 | 17.04 | 8.23 | 11.66 | 32.57 | 42.45 |
EV/FCF |
22.97 | 24.65 | 16.95 | 14.45 | 12.41 | 17.18 | 8.29 | 11.69 | 32.79 | 42.90 |
Quick Ratio |
2.60 | 3.11 | 3.92 | 6.38 | 5.28 | 9.83 | 7.62 | 6.31 | 3.95 | 2.24 |
Current Ratio |
2.92 | 3.35 | 4.39 | 6.89 | 5.60 | 10.08 | 7.91 | 6.66 | 4.20 | 2.40 |
Net Debt/EBITDA |
(8.83) | (2.96) | (3.66) | (3.67) | (1.68) | (3.37) | (2.41) | (2.35) | (1.68) | (3.58) |
Debt/Assets |
0.60% | 0.73% | 0.00% | 0.00% | 0.00% | 0.09% | 0.46% | 0.00% | 0.00% | 21.33% |
Debt/Equity |
0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.35 |
Asset Turnover |
0.91 | 0.92 | 0.80 | 0.80 | 0.74 | 0.72 | 0.85 | 0.94 | 1.10 | 1.35 |
Operating CF/Net income |
1.45 | 1.42 | 1.20 | 1.19 | 1.49 | 1.43 | 1.45 | 1.53 | 0.47 | 2.26 |
Capex/Depreciation |
0.07 | 0.23 | 0.02 | (0.09) | (0.05) | (0.55) | (0.50) | 0.20 | (3.49) | (1.80) |
| 14.79% | 23.56% | 20.92% | 23.08% | 25.03% | 23.70% | 29.11% | 32.31% | 111.15% | 27.19% | |
| 11.71% | 19.11% | 17.51% | 20.11% | 22.60% | 21.55% | 26.02% | 28.34% | 89.27% | 13.49% | |
ROIC |
9.98% | 28.31% | 48.42% | 100.32% | 51.09% | 96.37% | 71.82% | 80.92% | 32.32% | 141.16% |
Return on Tangible Assets |
30.56% | 41.90% | 29.77% | 23.70% | 51.16% | 24.50% | 34.94% | 37.35% | 135.73% | 21.13% |
Average Days of Receivables |
28.66 | 29.19 | 31.12 | 28.21 | 27.55 | 27.02 | 23.73 | 25.55 | 64.64 | 44.26 |
Research and Development Expense of Revenue |
33.48% | 36.57% | 38.22% | 32.60% | 31.11% | 32.43% | 29.04% | 29.95% | 25.36% | 29.32% |
Selling, General and Administrative Expense of Revenue |
58.93% | 41.53% | 38.20% | 38.04% | 33.43% | 29.76% | 32.75% | 32.35% | 39.21% | 55.63% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
11.10% | 9.09% | 10.15% | 10.56% | 11.73% | 9.48% | 9.56% | 9.45% | 8.39% | 8.68% |
Graham Net Nets |
0.08 | 0.06 | 0.14 | 0.19 | 0.10 | 0.14 | 0.19 | 0.13 | 0.05 | 0.05 |
Graham Number |
11.49 | 14.14 | 10.65 | 10.02 | 7.98 | 9.69 | 7.79 | 5.91 | 6.54 | 0.77 |
Earnings Yield |
2.70% | 2.68% | 4.26% | 4.71% | 4.39% | 3.52% | 6.86% | 4.87% | 6.23% | 0.95% |
Free Cash Flow Yield |
3.92% | 3.77% | 5.06% | 5.57% | 7.31% | 4.99% | 9.76% | 7.49% | 2.94% | 2.24% |
Revenue per Share |
7.33 | 6.54 | 4.66 | 3.76 | 3.16 | 3.07 | 2.68 | 2.18 | 1.40 | 0.74 |
Operating CF per Share |
1.37 | 1.92 | 1.22 | 1.13 | 1.45 | 1.32 | 1.19 | 1.00 | 0.54 | 0.17 |
Capex per Share |
0.00 | (0.02) | 0.00 | 0.00 | 0.00 | (0.01) | (0.01) | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
1.37 | 1.90 | 1.22 | 1.12 | 1.45 | 1.31 | 1.18 | 1.00 | 0.53 | 0.16 |
Cash per Share |
3.58 | 3.71 | 3.56 | 4.04 | 1.93 | 3.82 | 2.41 | 1.79 | 0.78 | 0.47 |
Shareholders Equity per Share |
6.24 | 6.58 | 4.89 | 4.70 | 3.25 | 4.53 | 3.25 | 2.39 | 1.68 | 0.37 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
6.24 | 6.58 | 4.89 | 4.70 | 3.25 | 4.53 | 3.25 | 2.39 | 1.68 | 0.37 |
Free Cash Flow |
141.79 | 196.12 | 126.54 | 119.91 | 167.42 | 150.73 | 135.03 | 115.37 | 60.52 | 18.20 |
Working Capital |
319.38 | 330.83 | 354.13 | 426.76 | 218.92 | 431.01 | 268.52 | 201.25 | 94.62 | 38.32 |
Capital Expenditures |
(0.21) | (2.17) | (0.14) | (0.41) | (0.47) | (1.24) | (1.09) | (0.30) | (0.42) | (0.19) |
Net Current Asset Value |
296.62 | 310.64 | 343.82 | 417.67 | 218.51 | 430.11 | 266.23 | 201.01 | 94.62 | 38.32 |
EV/EBIT |
72.71 | 35.30 | 19.99 | 15.39 | 16.69 | 20.20 | 10.03 | 15.06 | 37.55 | 76.69 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
80.68 | 37.98 | 23.32 | 19.12 | 18.40 | 23.55 | 12.40 | 17.22 | 38.96 | 79.95 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
(1.70) | (3.57) | (34.70) | 7.63 | 8.54 | 1.34 | 2.07 | (2.27) | 0.23 | 0.53 |
Cash ROIC |
13.83% | 18.35% | 14.46% | 12.85% | 27.93% | 15.63% | 20.80% | 23.90% | 21.64% | 16.92% |
Accounts Receivable Turnover |
13.39 | 14.20 | 13.37 | 13.70 | 13.60 | 15.34 | 16.34 | 10.98 | 8.37 | 10.11 |
Accounts Payable Turnover |
0.47 | 0.66 | 0.44 | 0.57 | 0.60 | 0.62 | 0.70 | 0.62 | 0.65 | 1.14 |
Inventory Turnover |
1.03 | 1.08 | 0.94 | 0.97 | 1.07 | 1.08 | 1.08 | 1.12 | 1.03 | 1.03 |
Average Days of Payables |
1,137.56 | 515.74 | 979.72 | 811.74 | 477.45 | 690.11 | 499.82 | 578.54 | 881.07 | 406.15 |
Days of Inventory on Hand |
361.93 | 416.32 | 435.34 | 413.46 | 344.75 | 321.06 | 359.69 | 331.19 | 469.96 | 413.06 |
Average Receivables |
56.88 | 47.55 | 36.09 | 29.34 | 26.91 | 23.06 | 18.76 | 22.89 | 19.03 | 8.04 |
Average Payables |
27.91 | 16.39 | 14.69 | 9.44 | 8.73 | 9.05 | 7.90 | 8.42 | 5.43 | 1.81 |
Average Inventory |
12.64 | 10.07 | 6.92 | 5.54 | 4.95 | 5.17 | 5.08 | 4.65 | 3.45 | 2.01 |
Average Assets |
838.60 | 731.04 | 602.47 | 503.59 | 497.74 | 492.02 | 362.00 | 266.12 | 144.65 | 60.33 |
Average Common Equity |
663.70 | 593.15 | 504.27 | 438.82 | 449.57 | 447.26 | 323.53 | 233.43 | 116.17 | 29.94 |
Columns are period end dates